Skip to main content
Merck buys Tilos to expand antibody pipelines
6/12/2019

Tilos Therapeutics would be acquired by Merck for up to $773 million to expand the latter's pipelines in cancer, fibrosis, and autoimmune diseases. Tilos' pipelines include therapies that target latent TGFβ complex.

Full Story: